Introduction {#s1}
============

Non-melanoma skin cancers including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are the most frequent tumors in individuals of European descent [@pone.0080354-Miller1], [@pone.0080354-Leiter1]. Their incidences have increased considerably which is attributed to the aging population and high levels of sun exposure [@pone.0080354-Epstein1], [@pone.0080354-Alam1].

BCC is the most frequent type of skin cancer. Established risk factors for BCC include fair skin, blond or red hair, light eye color [@pone.0080354-Rubin1], UV-exposure, radiation, and immunosuppression [@pone.0080354-Epstein1], [@pone.0080354-Rubin1]. BCCs harbor mutations leading to activation of the hedgehog pathway [@pone.0080354-Epstein1]. Inactivating mutations in the tumor suppressor *PTCH1* were first identified in patients with basal cell nevus syndrome, [@pone.0080354-Hahn1], [@pone.0080354-Johnson1] and subsequently reported in up to 90% of sporadic BCC [@pone.0080354-Epstein1], [@pone.0080354-Gailani1], [@pone.0080354-Aszterbaum1]. Activating mutations in other hedgehog pathway genes, such as *SMO*, *SHH*, or *GLI*, are found less frequently (∼10% of tumors) [@pone.0080354-Xie1]. BCC were also shown to harbor frequent UV-signature mutations in *TP53* [@pone.0080354-Ling1], [@pone.0080354-Ziegler1]. Recently novel therapies inhibiting the hedgehog signaling pathway have shown high efficacy in treating patients with inoperable or metastatic BCC [@pone.0080354-Sekulic1].

SCC is less frequent than BCC (ratio circa 1∶4) [@pone.0080354-Alam1]. UV-exposure is considered to be the most important etiologic factor in SCC [@pone.0080354-Leiter1]. SCC has the potential to metastasize, and may result in death, particularly in organ transplant recipients [@pone.0080354-Ulrich1]. The prognosis for metastatic SCC is poor, with ten-year survival rates of less than 10% [@pone.0080354-Alam1]. Genetic alterations in SCCs include activating mutations or gains of *RAS* genes [@pone.0080354-Pierceall1], as well as mutations in *TP53*, frequently with a C\>T or CC\>TT UV-signature [@pone.0080354-Brash1]. Other genetic events are overexpression or mutations of *EGFR*, losses of *CDKN2A* [@pone.0080354-Ratushny1], and inactivating mutations of *NOTCH* [@pone.0080354-Wang1].

Novel mutations in the promoter region of *TERT*, coding for the catalytic subunit of the telomerase holoenzyme, were identified in up to 71% of cutaneous melanomas in two recent studies [@pone.0080354-Huang1], [@pone.0080354-Horn1]. These mutations lead to increased *TERT* expression, most likely by creating ETS transcription factor binding sites [@pone.0080354-Huang1], [@pone.0080354-Horn1]. *TERT* promoter mutations were also found in a number of other common cancers, including hepatocellular cancer, bladder cancer, thyroid cancer and gliomas [@pone.0080354-Killela1]--[@pone.0080354-Griewank1]. In cutaneous tumors, *TERT* promoter mutations with high numbers of UV-signature mutations were also identified in atypical fibroxanthomas and pleomorphic dermal sarcomas, rare soft tissue tumors arising in heavily UV-damaged skin [@pone.0080354-Griewank2]. One current study reported a *TERT* promoter mutation in one of five SCCs [@pone.0080354-Killela1], and another recent publication found *TERT* promoter mutations in 78% of BCC and 50% of SCC [@pone.0080354-Scott1].

In our study we investigate the presence of *TERT* promoter mutations in BCCs and SCCs, and their associations with clinical and pathologic features.

Materials and Methods {#s2}
=====================

Sample selection {#s2a}
----------------

Samples of primary BCCs and SCCs were obtained from 66 patients treated in the Department of Dermatology, University Hospital Essen, Germany. The study was approved by the Institutional Review Board of the University of Duisburg-Essen (*Ethikkomission der Universität Duisburg-Essen*) under the IRB protocol number 12-4961-BO. All patients provided written informed consent.

DNA isolation {#s2b}
-------------

10 µm-thick sections were cut from formalin-fixed, paraffin-embedded tumor tissues. The sections were deparaffinized and tumor tissue was manually macrodissected. Genomic DNA was isolated using the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions.

Direct (Sanger) sequencing {#s2c}
--------------------------

PCR amplification of the *TERT* promoter region was performed using primers: hTERT_F ACGAACGTGGCCAGCGGCAG and hTERT_R CTGGCGTCCCTGCACCCTGG (474 bp product), or primers hTERT_short_F CAGCGCTGCCTGAAACTC and hTERT_short_R GTCCTGCCCCTTCACCTT (163bp product) as previously described [@pone.0080354-Horn1]. PCR products were used as templates for sequencing after purification with the QIAquick PCR Purification Kit (Qiagen). Sequencing chromatogram files were examined using Chromas (version 2.01, University of Sussex, Brighton, United Kingdom) or Sequencher (demo version 5.1, Gene Codes Corporation, Ann Arbor, MI, USA) software.

Results {#s3}
=======

Study cohort {#s3a}
------------

The study cohort consisted of 32 BCC and 34 SCC samples, from 43 males and 23 females. The median age was 72.6 years for SCC and 73.0 years for BCC. Histopathologic analysis was performed on all samples to assess histologic subtype, tumor thickness, cystic component, ulceration status, and presence of pigmentation for BCC, as well as tumor thickness, Clark level, acantholysis, lymphovascular involvement (LVI), perineural involvement (PNI), and presence of ulceration in SCC. Clinicopathologic characteristics are listed in [Table 1](#pone-0080354-t001){ref-type="table"}.

10.1371/journal.pone.0080354.t001

###### *TERT* promoter mutations identified in BCC and SCC.

![](pone.0080354.t001){#pone-0080354-t001-1}

                                       BCC          SCC
  -------------------------------- ------------ -----------
  *Mutations*                                   
  *c.-146C\>T*                      *10 (31%)*   *5 (15%)*
  *c.-124C\>T*                      *4 (13%)*    *5 (15%)*
  *c.-138_139CC\>TT*                 *2 (6%)*    *4 (12%)*
  *c.-124_125CC\>TT*                 *1 (3%)*    *2 (6%)*
  *c.-124C\>T, c.-126C\>T*             *0*       *1 (3%)*
  *c.-126_127CC\>TT, c.-146C\>T*     *1 (3%)*       *0*

*TERT* promoter mutation analysis {#s3b}
---------------------------------

Recurrent TERT promoter mutations were identified in both BCC and SCC. Mutations were located at Chr.5.1295228C\>T, Chr.5.1295228_1295229CC\>TT, Chr.5.1295242_1295243CC\>TT, or Chr.5.1295250C\>T. Alternatively mutations may be denoted based on their upstream location to the ATG initiation codon of *TERT*, as c.-124C\>T, c.-124_125CC\>TT, c.-138_139CC\>TT, and c.-146C\>T, respectively. For the rest of the manuscript we will refer to the mutations using this annotation.

In BCC, *TERT* promoter mutations were identified in 18 (56%) cases ([Table 1](#pone-0080354-t001){ref-type="table"}). Recurrent mutations were located at positions c.-124C\>T (n = 4, 13%), c.-124_125CC\>TT (n = 1, 3%), c.-138_139CC\>TT (n = 2, 6%), or c.-146C\>T (n = 11, 34%), as shown in [Figure 1](#pone-0080354-g001){ref-type="fig"}. One c.-146C\>T mutant tumor also harbored a c.-126_127CC\>TT mutation. Seventeen (50%) SCCs harbored *TERT* promoter mutations ([Table 1](#pone-0080354-t001){ref-type="table"}), which included c.-124C\>T (n = 6, 18%), c.-124_125CC\>TT (n = 2, 6%), c.-138_139CC\>TT (n = 4, 12%), and c.-146C\>T (n = 5, 15%). One c.-124C\>T case had a concomitant c.-126C\>T mutation. All identified mutations showed a UV-signature (C\>T and CC\>TT) [@pone.0080354-Pleasance1].

![Recurrent mutations identified in the *TERT* promoter of BCC and SCC.\
Representative sequencing chromatograms showing the wild type sequence (on top) and representative examples of the mutations identified in both basal and squamous cell carcinoma samples -- c.-124C\>T, c.-124_125CC\>TT, c.-138_139CC\>TT or c.-146C\>T (alternatively annotated according to the chromosome location as Chr.5. 1295228C\>T, Chr.5. 1295228_1295229CC\>TT, Chr.5. 1295242_1295243CC\>TT or Chr.5.1295250C\>T, respectively). All presented mutations were found in both tumor cohorts however the presented chromatograms are from a BCC, SCC, BCC, and BCC, respectively.](pone.0080354.g001){#pone-0080354-g001}

Associations of clinical and pathologic parameters with *TERT* promoter mutation status {#s3c}
---------------------------------------------------------------------------------------

Apart from a small, statistically significant (p = 0.046) difference in age between patients with *TERT* promoter-mutant BCCs (median 75.5 years) and those with *TERT* promoter-wild type BCCs (median 71.0 years), there were no statistically significant associations of *TERT* mutation status with clinicopathologic parameters ([Table 2](#pone-0080354-t002){ref-type="table"} and [3](#pone-0080354-t003){ref-type="table"}).

10.1371/journal.pone.0080354.t002

###### Associations of clinical and pathologic parameters in BCC with *TERT* promoter mutation status.

![](pone.0080354.t002){#pone-0080354-t002-2}

  Parameter                 Level          All cases    *TERT^wt^*    *TERT^mut^*   P value[\*\*](#nt102){ref-type="table-fn"}
  ------------------ ------------------- ------------- ------------- ------------- --------------------------------------------
  Age at diagnosis         Median             73           71.0          75.5                         0.046
  (years)                   Range           30--90        30--87        52--90     
  Sex                      Female             10             4             6                           1.00
                            Male              22            10            12       
  Tumor location         Head & neck          23            10            13                           0.36
                         Extremities           2             0             2       
                            Trunk              7             4             3       
  Tumor thickness          Median           1.2 mm        1.1 mm        1.35 mm                        0.16
                            Range         0.6--4.1 mm   0.6--2.8 mm   0.8--4.1 mm  
  Histologic type          Nodular            15             7             8                           0.20
                        Micronodular           5             1             4       
                         Superficial           8             5             3       
                        Infiltrative           3             0             3       
                      Infundibulocystic        1             1             0       
  Cystic component           No               24            10            14                           0.70
                             Yes               8             4             4       
  Ulceration                 No               17            10             7                           0.07
                             Yes              15             4            11       
  Pigment                    No               31            14            17                           1.00
                             Yes               1             0             1       

*TERT^wt^*  =  *TERT* promoter wild-type; *TERT^mut^*  =  *TERT* promoter mutant.

Based on chi-squared or Fisher exact tests for categorical variables, and on Mann-Whitney test for continuous variables. Cases with missing data were excluded from statistical analyses.

Histologic parameters analyzed were based on the World Health Organization\'s classification and histologic criteria[@pone.0080354-KossardS1]. Tumor thickness was measured as for cutaneous melanomas[@pone.0080354-deVriesE1].

10.1371/journal.pone.0080354.t003

###### Associations of clinical and pathologic parameters in SCC with *TERT* mutation status.

![](pone.0080354.t003){#pone-0080354-t003-3}

  Parameter                                                Level                All cases      *TERT^wt^*    *TERT^mut^*    P value[\*\*](#nt106){ref-type="table-fn"}
  ------------------------------------------- ------------------------------- -------------- -------------- -------------- --------------------------------------------
  Age at diagnosis                                        Median                   72.6           76.8           72.5                          0.69
  (years)                                                  Range                  46--95         46--90         52--95     
  Sex                                                     Female                    13             7              6                            0.72
                                                           Male                     21             10             11       
  Tumor location                                        Head & neck                 25             11             14                           0.80
                                                        Extremities                 5              3              2        
                                                           Trunk                    2              1              1        
                                                       Missing data                 2              2              0        
  Tumor thickness                                         Median                 3.95 mm         4.7 mm         3.9 mm                         0.95
                                                           Range               2.8--10.0 mm   2.8--10.0 mm   3.0--10.0 mm  
  Clark level                                               III                     6              5              1                            0.13
                                                            IV                      17             6              11       
                                                             V                      10             5              5        
  Grade                                           1 (well differentiated)           8              4              4                            0.72
                                               2 (moderately differentiated)        16             7              9        
                                                 3 (poorly differentiated)          10             6              4        
  Acantholysis                                              No                      29             15             14                           1.00
                                                            Yes                     5              2              3        
  Ulceration                                                No                      19             8              11                           0.30
                                                            Yes                     15             9              6        
  Desmoplasia                                               No                      30             14             16                           0.48
                                                            Yes                     3              2              1        
                                                       Missing data                 1              1              0        
  Perineural invasion                                       No                      28             15             13                           0.66
                                                            Yes                     6              2              4        
  Lymphovascular                                            No                      33             16             17                           1.00
  invasion                                                  Yes                     1              1              0        
  Mean survival                                                                                   42.5           68.6         0.51[\*](#nt105){ref-type="table-fn"}
  (months)[\*](#nt105){ref-type="table-fn"}                                                   (33.7--51.4)   (57.5--79.7)  

*TERT^wt^*  =  *TERT* promoter wild-type; *TERT^mut^*  =  *TERT* promoter mutant.

Estimates of mean survival from Kaplan Meier method (median survival not reached); p value estimated using log-rank test.

Based on chi-squared or Fisher exact tests for categorical variables, and on Mann-Whitney test for continuous variables. Cases with missing data were excluded from statistical analyses.

Histologic parameters analyzed were based on the World Health Organization\'s classification and histologic criteria[@pone.0080354-WeedonD1]. Clark level of invasion and tumor thickness were measured as for cutaneous melanomas[@pone.0080354-deVriesE1].

Discussion {#s4}
==========

BCC and SCC harbor distinct patterns of genetic alterations. BCC have genetic alterations activating the hedgehog signaling pathway. In contrast, SCC show alterations leading to activation of the MAPK and AKT signaling pathway, such as overexpression or mutations of genes such as *RAS*, *EGFR*, or *PIK3CA* [@pone.0080354-Ratushny1], [@pone.0080354-Wang1]. Losses of *CDKN2A* [@pone.0080354-Ratushny1] and inactivation of *NOTCH* [@pone.0080354-Wang1] are also frequent in SCC, but not in BCC. The only previously recognized common genetic event in both tumors is *TP53* mutations. We found *TERT* promoter mutations in a substantial proportion of both BCC and SCC. The frequency of these mutations in BCC, SCC, melanoma [@pone.0080354-Huang1], [@pone.0080354-Horn1] and other cancers [@pone.0080354-Killela1] suggests that increased expression of the holoenzyme telomerase is an important event in a wide range of human malignancies.

The role of UV-mediated tumorigenesis in BCC and SCC is supported by epidemiologic data and by the presence of UV-signature mutations in *TP53* (BCC and SCC), *PTCH1* (BCC) or *RAS* (SCC) [@pone.0080354-Leiter1], [@pone.0080354-Epstein1], [@pone.0080354-Rubin1], [@pone.0080354-Ling1], [@pone.0080354-Brash1]. The mutations we identified in the *TERT* promoter have a UV-signature with C\>T or CC\>TT changes, consistent with an etiologic role for UV exposure. However, c.-124C\>T and c.-146C\>T mutations have also been identified in cancer types such as hepatocellular cancer, bladder cancer, thyroid cancer and gliomas, in which UV-induced mutations are unlikely [@pone.0080354-Killela1]--[@pone.0080354-Vinagre1]. CC\>TT alterations are considered virtually pathognomonic of UV-induction [@pone.0080354-Brash1], [@pone.0080354-Pleasance1] and were rare or not described in the aforementioned tumors, however were frequent in cutaneous melanoma and other cutaneous tumors occurring on sun-damaged skin [@pone.0080354-Horn1], [@pone.0080354-Griewank2]. There is a rare C\>T SNP (rs35550267) at position c.-139. To our knowledge no known SNP has been reported at c.-125 (dbSNP). Thus, although we cannot exclude that of the ten CC\>TT alterations detected (six c.-138_139CC\>TT, three c.-124_125CC\>TT and one c.-126_127CC\>TT) some, or potentially even all, represent a preexisting C\>T variation with an additional C\>T mutation, we do believe these alterations, found in 13% of BCC and 18% of SCC, most likely primarily represent UV-exposure tandem mutations, arguing for UV-exposure inducing *TERT* promoter mutations in these tumors. Future larger studies with paired tumor and constitutional DNA should be able to definitively address the role of dipyrimidine mutations in the *TERT* promoter of BCC and SCC.

Matched blood samples of the tumors analyzed in our study were not available, precluding us from directly excluding the presence of germ-line mutations at the mutation hotspots c.-124 or c.-146. However, germ-line mutations at these hotspots have not been observed in various *TERT* promoter mutation studies which compared paired tumor and normal (blood) tissue isolated DNA [@pone.0080354-Huang1]--[@pone.0080354-Killela1], [@pone.0080354-Griewank1], [@pone.0080354-Scott1], nor were they present in the 1000 Genomes database [@pone.0080354-Genomes1]. This makes it almost certain that the mutations detected at these loci in our tumor cohort were somatically acquired.

Functional studies showed that the identified *TERT* promoter mutations cause a 2-4 fold increase in gene expression [@pone.0080354-Huang1], [@pone.0080354-Horn1], most likely by introducing ETS transcription binding sites [@pone.0080354-Huang1]--[@pone.0080354-Killela1]. Although multiple adjacent nucleotides could acquire UV-induced C\>T or CC\>TT mutations ([Figure 1](#pone-0080354-g001){ref-type="fig"}), the mutations identified in BCC and SCC in our study almost exclusively affected the *TERT* promoter at the described functionally relevant hotspots. This clearly implies a high selection pressure for these mutations, resulting in overexpression of the telomerase holoenzyme. Telomerase expression in tumors is critical for maintaining telomere length and chromosomal stability, which allows cells to continuously proliferate without becoming genetically unstable, and avoiding apoptosis or senescence [@pone.0080354-Blackburn1], [@pone.0080354-Gunes1].

The only significant correlation with clinical parameters observed in our cohort, was a slight difference in age between *TERT* promoter mutant and non-mutant BCC. Our cohort is small and larger more detailed follow up studies will be required to verify this finding and to determine if additional clinicopathologic correlations with *TERT* promoter mutation status can be identified.

In summary, our study identifies *TERT* promoter mutations with a UV-signature as frequent events in BCC and SCC non-melanoma skin cancer. Similar results independently validating these findings were recently reported by Scott et al., who found recurrent *TERT* promoter mutations in 78% of BCC and 50% of SCC [@pone.0080354-Scott1]. Future studies will be required to determine whether *TERT* promoter mutations have prognostic implications or may be targeted therapeutically. This would be especially valuable in patients with metastatic SCC for whom prognosis is poor and effective therapies are lacking.
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